CX.5 SHAPE - Randomization Milestone

Wednesday, November 15, 2017

400 Patients Randomized!

Congratulations to Dr. Ramon Smolders and the team at Erasmus MC in Rotterdam, The Netherlands for enrolling the 400th patient to the SHAPE study! Congratulations also to Dr. Felix Hilpert and the team at Agaplesion Diakonieklinikum in Hamburg, Germany for enrolling the 1st German patient.

On behalf of the SHAPE trial committee, we would like to thank everyone for their support of the trial. If you have any questions or are looking for more information please contact study coordinator, Andrea Hiltz.

About the trial

A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer. (SHAPE)

The reason this study is being done is to see if a simple hysterectomy is as good as a radical hysterectomy in preventing cancer of the cervix from returning, and whether, because less tissue surrounding the uterus is removed during surgery, there are fewer side-effects after the surgery and in the long-term.

Eligibility: Histologically confirmed adenocarcinoma, squamous, or adenosquamous cancer of the cervix. Diagnosis has been made by LEEP, cone or cervical biopsy and has been reviewed and confirmed by the local reference gynecological pathologist.